Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Fellatio
← New Search

Fellatio

Educational clinical summary of Fellatio for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This document provides evidence-based medical information for educational and reference purposes. It is not intended to provide specific medical advice, and clinical judgment must always supersede general guidelines. Healthcare professionals should consider individual patient circumstances, local epidemiology, and the most current guidelines when making treatment decisions. Patients should consult with their healthcare provider for any health concerns.

Overview

  • Definition: Fellatio is a form of oral sex involving oral stimulation of the penis. It typically involves using the mouth, lips, and tongue to stimulate the glans, shaft, or scrotum.
  • Epidemiology: Oral sex is a common sexual practice across diverse populations. Studies indicate that a significant majority of sexually active individuals engage in oral sex at some point in their lives, with prevalence varying by age, sexual orientation, and cultural context. It is often perceived as a "safer" sexual activity compared to vaginal or anal intercourse, which can lead to reduced condom use and a potential underestimation of associated health risks.
  • Classification: While fellatio itself is a sexual act and not a medical condition requiring classification, its medical relevance primarily stems from the potential for the transmission of sexually transmitted infections (STIs) and the occurrence of oral trauma.

Pathophysiology

Mechanism

The medical implications of fellatio primarily arise from two main mechanisms: - Sexual Transmitted Infection (STI) Transmission: - Direct contact between the oral mucosa (mouth, throat) and penile secretions (semen, pre-ejaculate) or penile skin/mucosa allows for the exchange of pathogens. - Pathogens can enter the oral cavity through microscopic breaks in the mucosa, directly penetrate epithelial cells, or colonize mucosal surfaces. - The oral cavity, particularly the tonsillar crypts and pharyngeal lymphoid tissue, can serve as a reservoir for certain STIs (e.g., Neisseria gonorrhoeae, Chlamydia trachomatis, Human Papillomavirus [HPV]). - Oral Trauma: - Physical forces exerted by the mouth, teeth, or tongue during the act can lead to mechanical injury. - Suction, biting, or aggressive movements can cause abrasions, lacerations, hematomas, and, rarely, more severe injuries to the oral structures (lips, tongue, buccal mucosa, frenulum, palate, teeth). - The presence of sharp dental prosthetics or significant dental irregularities can increase the risk of trauma.

Risk Factors

  • For STIs:
    • Unprotected Fellatio: Lack of barrier protection (e.g., condoms).
    • Multiple Sexual Partners: Increases exposure to diverse pathogen strains.
    • Partner with Known STI: Direct exposure to an infected individual.
    • Concurrent Anogenital STIs: Presence of STIs in other body sites may increase susceptibility or viral/bacterial load, facilitating transmission.
    • Mucosal Trauma: Pre-existing oral lesions, inflammation, or micro-abrasions can create entry points for pathogens.
    • High-Risk Sexual Networks: Engaging with partners who have a higher prevalence of STIs.
    • Lack of STI Screening: Undiagnosed STIs in partners.
  • For Oral Trauma:
    • Aggressive or Vigorous Technique: Increased mechanical force.
    • Dental Factors: Sharp teeth, malocclusion, braces, or prosthetics.
    • Lack of Lubrication: Can increase friction.
    • Foreign Objects: Use of objects not intended for oral sexual activity.
    • Intoxication: Impaired judgment from alcohol or drug use.

Protective Factors

  • For STIs:
    • Condom Use: While not 100% effective, consistent and correct use of condoms during fellatio significantly reduces the risk of STI transmission (e.g., for HIV, gonorrhea, chlamydia).
    • Limiting Sexual Partners: Reduces exposure risk.
    • Mutual Monogamy with Tested Partners: If both partners are tested negative for STIs and are mutually monogamous.
    • Regular STI Screening: Early detection and treatment of STIs in oneself and partners.
    • Vaccination: HPV vaccine (Gardasil 9) prevents HPV-related cancers and genital warts. Hepatitis B vaccine prevents HBV infection.
    • PrEP (Pre-Exposure Prophylaxis) for HIV: For individuals at high risk of HIV acquisition, though oral transmission risk is lower than anal/vaginal.
  • For Oral Trauma:
    • Gentle Technique: Avoiding excessive force or biting.
    • Adequate Lubrication: Natural or artificial.
    • Good Oral Hygiene: Reduces inflammation and potential for secondary infection.

Clinical Presentation (of Complications Related to Fellatio)

Signs and Symptoms

  • Cardinal Features:
    • STIs:
      • Gonorrhea/Chlamydia: Pharyngitis (sore throat, erythema, exudates), often asymptomatic.
      • Herpes Simplex Virus (HSV): Oral cold sores/ulcers (vesicular lesions progressing to painful ulcers on lips, tongue, or buccal mucosa).
      • Syphilis: Oral chancre (painless ulcer, typically firm and well-demarcated) on lips, tongue, or pharynx.
      • HPV: Oral warts (papillomatous or verrucous lesions, often flesh-colored, varying in size, may be asymptomatic).
      • HIV: Acute retroviral syndrome (fever, fatigue, rash, lymphadenopathy, pharyngitis) in primary infection, though not specific to oral transmission.
    • Trauma:
      • Oral pain, bleeding (hematoma, ecchymosis), swelling, dysphagia, difficulty speaking, lacerations, abrasions.
  • Early Signs: Mild sore throat, subtle oral lesions, minor oral discomfort or bleeding.
  • Advanced Signs: Extensive oropharyngeal inflammation, large ulcerative lesions, significant bleeding, systemic symptoms of disseminated STIs (e.g., rash, arthritis from disseminated gonorrhea), deep space neck infections (rare), persistent oral lesions concerning for malignancy.
  • Atypical Presentations: Asymptomatic STI carriage (especially pharyngeal gonorrhea/chlamydia), unusual oral lesions, prolonged healing of traumatic injuries.

Physical Examination (of Complications)

  • Inspection:
    • Oral Cavity and Oropharynx: Examine lips, buccal mucosa, gingiva, tongue, palate, tonsils, and posterior pharyngeal wall for:
      • Lesions: Ulcers, vesicles, papules, plaques, warts, erosions. Note size, location, color, and margins.
      • Inflammation: Erythema, edema, exudates (e.g., on tonsils).
      • Traumatic Injuries: Abrasions, lacerations, petechiae, hematomas, frenulum tears.
    • Perioral and Penile Examination: Assess for concurrent or source lesions.
  • Palpation:
    • Cervical and Submandibular Lymph Nodes: Check for lymphadenopathy (tender, mobile in infection; firm, fixed in malignancy).
    • Oral Structures: Assess for tenderness, induration, or fluctuance (abscess).
  • Special Tests: Not typically required for initial assessment, but can include:
    • Cranial Nerve Examination: If neurological involvement is suspected (rare, e.g., HSV encephalitis or tertiary syphilis).
    • Dental Evaluation: For suspected dental injury or avulsion.

Diagnostic Approach (for Complications Related to Fellatio)

History Taking

  • Key Questions:
    • Sexual History: Detailed, non-judgmental sexual history, including specific types of sexual contact (oral, anal, vaginal), protection methods used (condoms), number of partners, recent partners, and any known STI status of partners.
    • Symptoms: Onset, duration, character, and severity of oral pain, sore throat, lesions, bleeding, or dysphagia.
    • STI History: Previous STI diagnoses, treatments, and adherence.
    • Vaccination Status: HPV, Hepatitis B.
    • Oral Trauma: Circumstances surrounding the injury, use of force, presence of foreign objects.
    • Dental History: Presence of dental prosthetics, sharp teeth, recent dental work.
    • Systemic Symptoms: Fever, chills, rash, weight loss, lymphadenopathy.
    • Substance Use: Alcohol or recreational drug use (can impair judgment and increase risk of trauma or unprotected sex).
  • Red Flags:
    • Severe dysphagia or odynophagia (suggesting airway compromise or deep infection).
    • Significant oral hemorrhage.
    • Rapidly spreading oral or pharyngeal inflammation/infection.
    • Systemic signs of sepsis (fever, tachycardia, hypotension).
    • Suspicion of non-accidental injury or sexual abuse, especially in pediatric populations.

Laboratory Tests (for Complications)

  • First-Line:
    • STI Screening (Pharyngeal Swabs): Nucleic Acid Amplification Tests (NAAT) for Neisseria gonorrhoeae and Chlamydia trachomatis from the pharynx in symptomatic individuals and high-risk asymptomatic individuals.
    • Oral Lesion Swabs: PCR or viral culture for HSV if vesicular or ulcerative lesions are present.
    • Syphilis Serology: Rapid Plasma Reagin (RPR) or Venereal Disease Research Laboratory (VDRL) with confirmatory fluorescent treponemal antibody absorption (FTA-ABS) or Treponema pallidum particle agglutination (TP-PA) if oral chancre or other symptoms suggest syphilis.
    • HIV Screening: Fourth-generation HIV antigen/antibody test (Ag/Ab) for all individuals with suspected STIs or high-risk sexual activity.
    • Hepatitis Serology: Hepatitis B surface antigen (HBsAg), anti-HBs, anti-HBc for Hepatitis B. Hepatitis C antibody for Hepatitis C.
  • Confirmatory:
    • Biopsy: For persistent or atypical oral lesions, particularly those suspected to be HPV-related or malignant.
    • Specific PCR Tests: For less common pathogens if clinically indicated.
  • Monitoring:
    • Test-of-Cure: Recommended for pharyngeal gonorrhea and chlamydia (3-4 weeks post-treatment), due to higher rates of treatment failure and asymptomatic persistence compared to genital sites.
    • Repeat HIV testing: For individuals with acute HIV infection or ongoing high-risk exposures.
    • HPV Lesion Monitoring: Clinical surveillance for recurrence or progression, particularly for high-risk HPV types.

Imaging (for Complications)

  • Recommended:
    • Plain Radiographs: For suspected dental avulsion, mandibular fracture, or foreign body ingestion/aspiration in trauma cases.
    • CT Scan (Computed Tomography): With contrast if deep space neck infection (e.g., peritonsillar abscess, Ludwig's angina), extensive soft tissue trauma, or salivary gland involvement is suspected.
  • Advanced:
    • MRI (Magnetic Resonance Imaging): May provide better soft tissue detail for complex deep space infections, vascular injury, or suspected malignancy if CT is equivocal.
    • Panoramic Radiograph (Panorex): Useful for assessing the entire dentition and mandible.

Management (of Complications Related to Fellatio)

Acute Management

  • Immediate:
    • Airway Management: Prioritize in cases of severe oropharyngeal swelling or deep space infection. May require intubation or emergency tracheostomy.
    • Hemorrhage Control: Direct pressure for oral bleeding, surgical consultation if severe.
    • Pain Control: Analgesics (e.g., NSAIDs, opioids for severe pain).
  • Stabilization:
    • Empiric Antibiotics: For suspected bacterial pharyngitis or oral infections (e.g., Ceftriaxone 500 mg IM single dose for suspected gonococcal pharyngitis, often with Azithromycin 1g oral single dose or Doxycycline 100 mg orally BID for 7 days for concomitant chlamydia).
    • Antivirals: For severe primary HSV oral infections (e.g., Acyclovir, Valacyclovir).
    • Tetanus Prophylaxis: For deep or contaminated oral wounds.
  • Emergency: Surgical drainage of abscesses (e.g., peritonsillar abscess), repair of extensive lacerations, control of major hemorrhage.

Chronic Management

  • Pharmacological:
    • STIs:
      • Gonorrhea: Ceftriaxone 500 mg IM as a single dose (or 1g if weight ≥150 kg) is the recommended first-line treatment for uncomplicated pharyngeal gonorrhea (CDC 2021 STD Treatment Guidelines).
      • Chlamydia: Doxycycline 100 mg orally twice daily for 7 days. Azithromycin 1g orally single dose is an alternative but less effective for pharyngeal infection.
      • Syphilis: Benzathine Penicillin G (Bicillin L-A) 2.4 million units IM single dose for primary, secondary, or early latent syphilis.
      • HSV: Acyclovir, Valacyclovir, or Famciclovir for primary infection and for episodic or suppressive therapy of recurrent outbreaks.
      • HIV: Antiretroviral therapy (ART) is indicated for all individuals with HIV.
    • HPV: Topical agents (imiquimod, podophyllotoxin) or ablative therapies (cryotherapy, excision, laser) for symptomatic oral warts. Regular surveillance for suspicious lesions.
    • Trauma: Oral antibiotics (e.g., amoxicillin-clavulanate) for prevention of secondary infection in significant oral wounds. Analgesics for pain.
  • Non-pharmacological:
    • Counseling: Comprehensive risk-reduction counseling, including safer sex practices, condom use, partner notification, and STI screening.
    • Hygiene: Meticulous oral hygiene, warm saline rinses for oral wounds/lesions.
    • Dietary Modification: Soft diet for patients with significant oral pain or trauma.
    • Smoking and Alcohol Cessation: Important for individuals with HPV-associated lesions to reduce oral cancer risk.
  • Monitoring:
    • STI Follow-up: Test-of-cure for pharyngeal gonorrhea and chlamydia 3-4 weeks post-treatment. Retest for other STIs (e.g., HIV, syphilis) if ongoing risk behavior.
    • HPV Lesion Monitoring: Regular oral examinations for recurrence or progression, referral to oral medicine/oncology for persistent or suspicious lesions.
    • Trauma Follow-up: Assess wound healing, manage pain, identify complications.

Treatment Algorithms (for Complications)

  • First-Line: Follow specific national/international STI treatment guidelines (e.g., CDC STD Treatment Guidelines). For oral trauma, local wound care, pain management, and consideration of antibiotics based on wound severity.
  • Second-Line:
    • STIs: Alternative antibiotic regimens for resistant strains (e.g., culture-guided therapy for resistant gonorrhea) or for patients with allergies.
    • HPV: Different modalities for resistant or recurrent warts.
  • Refractory Cases:
    • STIs: Referral to infectious disease specialists.
    • Oral Lesions: Referral to oral and maxillofacial surgeons, ENT specialists, or oncologists for persistent, atypical, or potentially malignant oral lesions.

Complications

  • Common:
    • Infectious: Pharyngeal gonorrhea, pharyngeal chlamydia, oral HSV (herpes labialis, herpetic pharyngitis), oral syphilis (chancre), oral HPV (warts).
    • Traumatic: Minor oral abrasions, lacerations, petechiae on the palate, sublingual hematomas, frenulum tears.
  • Serious:
    • Infectious:
      • HIV Transmission: While less efficient than anal/vaginal sex, oral transmission of HIV is possible, especially with presence of oral lesions or high viral load.
      • Disseminated Gonococcal Infection: Rare, but can lead to arthritis, dermatitis, tenosynovitis, or endocarditis.
      • Secondary/Tertiary Syphilis: Untreated primary syphilis can progress, leading to systemic complications.
      • HPV-Associated Oropharyngeal Cancer: Primarily squamous cell carcinoma of the tonsils, base of tongue, or other pharyngeal sites, strongly linked to HPV-16.
      • Deep Space Neck Infections: Rare, but severe pharyngeal infections can spread to cause Ludwig's angina, parapharyngeal abscess, or retropharyngeal abscess, potentially leading to airway obstruction or mediastinitis.
      • Hepatitis Transmission: Hepatitis B and C transmission are possible through sexual contact, though less common via oral routes than blood-to-blood or unprotected penetrative sex.
    • Traumatic: Significant oral hemorrhage, dental avulsion, mandibular fracture (rare), aspiration pneumonitis (from aspiration of blood or oral contents).
  • Long-term:
    • Chronic viral infections (HIV, HSV, HPV).
    • Recurrent oral lesions (HSV, HPV).
    • Chronic pain from trauma or recurrent infections.
    • Psychological distress and anxiety related to STI diagnosis or chronic conditions.
    • Increased risk of oral and oropharyngeal cancer, particularly for those with chronic high-risk HPV infection, especially when combined with tobacco and alcohol use.

Prognosis (for Complications)

  • Factors:
    • Type of Complication: Prognosis varies greatly depending on the specific STI or traumatic injury.
    • Timely Diagnosis and Treatment: Early intervention generally leads to better outcomes.
    • Patient's Immune Status: Immunocompromised individuals (e.g., HIV-positive) may experience more severe or recurrent infections.
    • Adherence to Treatment: Non-adherence can lead to treatment failure, recurrence, and progression.
    • Recurrence Rate: Some conditions (e.g., HSV, HPV warts) are prone to recurrence.
    • Presence of Co-factors: Tobacco and alcohol use significantly worsen the prognosis for HPV-associated oral cancers.
  • Survival: Generally excellent for most treatable bacterial STIs and minor oral trauma. Prognosis for HPV-associated oropharyngeal cancer is often better than non-HPV related oral cancers, especially with early detection, but depends on stage, treatment response, and patient factors.
  • Quality of Life: Can be significantly impacted by chronic or recurrent STIs, persistent oral pain, psychological distress, and the effects of cancer treatment (e.g., dysphagia, speech changes).

Prevention

Primary

  • Safer Sex Practices:
    • Condom Use: Consistent and correct use of condoms or dental dams during oral sex significantly reduces the risk of STI transmission.
    • Limiting Partners: Reducing the number of sexual partners decreases exposure risk.
    • Mutual Monogamy: With partners who have been tested for STIs and are confirmed negative.
  • STI Screening: Regular STI screening for sexually active individuals, especially those with multiple partners, new partners, or those in high-risk groups.
  • Vaccination:
    • HPV Vaccine: Gardasil 9 is recommended for individuals aged 9 to 45 years to prevent HPV-related cancers (including oropharyngeal) and genital warts.
    • Hepatitis B Vaccine: Recommended for all infants, children, adolescents, and adults at risk.
  • Risk Reduction Counseling: Education on STI transmission routes, symptoms, testing, and prevention strategies.
  • Trauma Prevention: Gentle technique, avoiding sharp objects in the mouth, and ensuring adequate lubrication.

Secondary

  • Early Detection and Intervention:
    • Prompt STI Testing: For individuals presenting with symptoms suggestive of oral STIs or following high-risk exposure.
    • Partner Notification and Treatment: Essential to prevent re-infection and further transmission.
    • Oral Screening: Regular oral examinations, especially for high-risk individuals (e.g., those with HPV infection, tobacco/alcohol use) to detect precancerous lesions or early-stage cancers.

Tertiary

  • Preventing Complications in Established Conditions:
    • Adherence to Treatment: For STIs and other complications to prevent progression and long-term sequelae.
    • Surveillance for HPV-Associated Cancers: Regular follow-up for individuals with high-risk HPV infection or previous HPV-related lesions.
    • Counseling on Co-factors: Strong recommendations for smoking cessation and reduced alcohol consumption for individuals at risk of oropharyngeal cancer.
    • Rehabilitation: For patients with significant functional impairment due to cancer treatment or severe trauma.

Special Populations

  • Pediatric:
    • Child Sexual Abuse: The presence of STIs or oral trauma in children is a strong indicator of possible child sexual abuse and requires immediate investigation, documentation, and mandatory reporting to child protective services.
    • Forensic Examination: Specialized forensic examination may be necessary.
  • Geriatric:
    • Undiagnosed STIs: STIs are often overlooked in older adults due to stereotypes and less frequent sexual history taking.
    • Comorbidities: Increased prevalence of comorbidities (e.g., diabetes, immunosuppression) may alter immune response, affect healing, and complicate STI management.
    • Medication Interactions: Potential for drug-drug interactions with STI treatments.
  • Pregnancy:
    • STI Management: Specific STI treatments may be contraindicated or require modification during pregnancy.
    • Vertical Transmission Risk: Certain STIs (e.g., HSV, syphilis, HIV) can be transmitted vertically to the fetus, with varying risks depending on the STI and presence of active lesions during childbirth.
    • Counseling: Crucial for pregnant individuals regarding STI risks, prevention, and treatment to protect both maternal and fetal health.
  • Comorbidities:
    • Immunocompromised Individuals: Patients with HIV, transplant recipients, or those on immunosuppressive therapy are at higher risk for severe, persistent, or recurrent infections (e.g., HSV, HPV, fungal infections) and may require more aggressive or prolonged treatment.
    • Dental Disease: Poor oral health or pre-existing dental disease can exacerbate oral trauma and increase the risk of secondary bacterial infections.

Clinical Pearls

  • Diagnostic:
    • Comprehensive Sexual History: Always take a detailed and non-judgmental sexual history when evaluating oral lesions, pharyngitis, or other oral symptoms, especially in sexually active individuals. Do not assume oral symptoms are non-sexual.
    • Asymptomatic Pharyngeal STIs: Pharyngeal gonorrhea and chlamydia are frequently asymptomatic, making targeted screening in high-risk populations crucial.
    • Look Beyond the Mouth: Always examine for concurrent STIs in genital/anal regions, as oral sex rarely occurs in isolation.
    • Consider HPV: Persistent or recurrent oral warts, or suspicious tonsillar/base-of-tongue lesions, should prompt consideration of HPV infection and potential for malignancy.
  • Treatment:
    • Follow Guidelines: Adhere strictly to the latest CDC STD Treatment Guidelines or equivalent national recommendations.
    • Partner Services: Emphasize partner notification and treatment to prevent reinfection and onward transmission.
    • Test-of-Cure: Remember to perform test-of-cure for pharyngeal gonorrhea and chlamydia due to potential for higher treatment failure rates.
    • Vaccination Counseling: Counsel eligible patients on HPV and Hepatitis B vaccination.
  • Pitfalls:
    • Underestimating Risk: Many patients and providers underestimate the risk of STI transmission through oral sex.
    • Incomplete Screening: Failing to screen for pharyngeal STIs in individuals engaging in oral sex, especially if symptomatic or high-risk.
    • Missed Co-infections: Failing to screen for other common STIs (HIV, syphilis, hepatitis) when one STI is diagnosed.
    • Delay in Cancer Diagnosis: Attributing persistent oral lesions or sore throat solely to minor irritation or common infections, thereby delaying diagnosis of HPV-associated oropharyngeal cancer.
    • Neglecting Pediatric Abuse: Missing signs of non-accidental injury or STIs in children.

Recent Updates

  • Guidelines:
    • CDC STD Treatment Guidelines (2021): Updated recommendations for gonorrhea treatment (Ceftriaxone 500 mg single dose) and emphasis on Doxycycline for chlamydia. Stronger recommendations for PrEP for HIV prevention.
    • WHO Guidelines: Ongoing updates regarding STI management, surveillance, and prevention strategies globally.
  • Evidence:
    • HPV-Associated Oropharyngeal Cancer: Growing body of evidence solidifying the link between high-risk HPV (especially HPV-16) and a significant proportion of oropharyngeal cancers, particularly tonsil and base-of-tongue SCC. Increased recognition of these cancers in non-smoking populations.
    • HPV Vaccination Impact: Data consistently shows a significant reduction in HPV prevalence, genital warts, and precancerous lesions following widespread HPV vaccination. Ongoing research into the direct impact on oropharyngeal cancer rates.
    • Emerging Antibiotic Resistance: Continued monitoring and reporting of antibiotic resistance patterns in N. gonorrhoeae, informing treatment guideline updates.
  • Controversies:
    • Optimal Screening Strategies: Debate regarding routine pharyngeal STI screening for asymptomatic individuals in various populations (e.g., men who have sex with men, adolescents).
    • Oral PrEP for HIV: While highly effective for preventing HIV from receptive anal/vaginal sex, the efficacy and need for PrEP for preventing HIV acquisition solely through receptive oral sex remains a topic of discussion due to the lower transmission efficiency.
    • Efficacy of Oral Dam/Dental Dam: While recommended for reducing STI transmission during oral-vaginal or oral-anal sex, their consistent use and efficacy specifically for fellatio are less studied and practical challenges exist.

Key References

  • Guidelines:
    • Centers for Disease Control and Prevention (CDC) STD Treatment Guidelines: Most current version (e.g., 2021 guidelines), accessible via the CDC website.
    • World Health Organization (WHO) Guidelines for the management of sexually transmitted infections: Global recommendations and public health strategies.
    • National Comprehensive Cancer Network (NCCN) Guidelines for Head and Neck Cancers: Provides detailed recommendations for the diagnosis, staging, and treatment of HPV-associated oropharyngeal cancers.
  • Studies:
    • Landmark Studies on HPV Vaccine Efficacy: Studies like those on Gardasil and Cervarix trials demonstrating high efficacy against HPV-related outcomes.
    • Epidemiologic Studies on Oral STI Prevalence: Research by institutions like the CDC, showing the prevalence of pharyngeal gonorrhea, chlamydia, and HPV in various populations.
    • Clinical Trials on STI Treatment Regimens: Studies supporting the efficacy of current antibiotic and antiviral regimens for various STIs.
  • Reviews:
    • Systematic Reviews on Oral Sex and STI Transmission: Comprehensive analyses detailing the evidence for transmission risks of various STIs via oral sexual contact.
    • Reviews on HPV-Associated Oropharyngeal Cancer: Publications in journals like JAMA Otolaryngology–Head & Neck Surgery, Cancer, and New England Journal of Medicine summarizing current understanding of etiology, diagnosis, and management.

Dr. Vivek's AI | For Educational Purposes Only